Pterostilbene as an agonist for the peroxisome proliferator-activated receptor alpha isoform
View Patent ↗Resveratrol has been reported to have hypolipidemic properties. We investigated whether resveratrol and its analogs: pterostilbene, piceatannol and resveratrol trimethyl ether, would activate the peroxisome proliferator-activated receptor alpha (PPARα) isoform. This nuclear receptor is proposed to mediate the activity of lipid-lowering drugs such as the fibrates. The four stilbenes and ciprofibrate (positive control) were evaluated for the activation of endogenous PPARα in H4IIEC3 cells transfected with a luciferase gene reporter construct. Pterostilbene demonstrated the highest induction of PPARα; the maximal response to pterostilbene was similar to that obtained with the hypolipidemic drug, ciprofibrate.
1. A method of lowering lipid levels in an individual comprising administering to an individual in need thereof a therapeutically effective amount of an edible pharmaceutical composition consisting essentially of an edible therapeutically effective unit dosage of isolated or chemically-synthesized pterostilbene and a pharmaceutically acceptable carrier, wherein the unit dosage of pterostilbene administered orally is effective to lower lipid levels in an individual.
2. A method of treating dyslipidemias in an individual at risk of cardiovascular disease by administering to an individual in need thereof a therapeutically effective amount of an edible pharmaceutical composition consisting essentially of an edible therapeutically effective unit dosage of isolated or chemically-synthesized pterostilbene for lowering lipid levels in an individual and a pharmaceutically acceptable carrier, wherein the unit dosage of pterostilbene administered orally is effective to treat dyslipidemias or reduce the risk of dyslipidemias in an individual.
3. A method of lowering lipid levels in an individual comprising administering to an individual in need thereof an effective amount of an edible nutraceutical composition consisting essentially of an edible therapeutically effective unit dosage of isolated or chemically-synthesized pterostilbene and a nutraceutically acceptable carrier, wherein the unit dosage of pterostilbene administered orally is effective to lower lipid levels in an individual and to treat or reduce the risk of dyslipidemias in an individual.